NCT04345406

Brief Summary

ACEIs as treatment for COVID19

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at below P25 for phase_3

Timeline
43mo left

Started Apr 2020

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Apr 2020Dec 2029

First Submitted

Initial submission to the registry

April 11, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 14, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

April 15, 2020

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

April 14, 2020

Status Verified

April 1, 2020

Enrollment Period

9.6 years

First QC Date

April 11, 2020

Last Update Submit

April 11, 2020

Conditions

COVID

Outcome Measures

Primary Outcomes (1)

  • number of patients with virological cure

    number of patients with virological cure

    6 months

Study Arms (2)

ACEIs

EXPERIMENTAL

ACEIs with conventional treatment for COVID19

Drug: ACEIsDrug: Conventional treatment

Conventional treatment of COVID19

EXPERIMENTAL

Conventional treatment of COVID19

Drug: Conventional treatment

Interventions

ACEIsDRUG

Captopril or enalapril

Also known as: Enalapril, Captopril
ACEIs
Conventional treatmentDRUG

alexoquine

Also known as: chloroquine
ACEIsConventional treatment of COVID19

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients infected with covid 19

You may not qualify if:

  • allergy or contraindications to the drug

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tanta University

Tanta, 35111, Egypt

Location

MeSH Terms

Interventions

EnalaprilCaptoprilChloroquine

Intervention Hierarchy (Ancestors)

DipeptidesOligopeptidesPeptidesAmino Acids, Peptides, and ProteinsProlineImino AcidsAmino Acids, CyclicAmino AcidsAminoquinolinesQuinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Sherief Abd-Elsalam, ass. prof.

    Tanta University Faculty of medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Sherief Abd-Elsalam

CONTACT

+201147773440sheriefabdelsalam@yahoo.com

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant professor of tropical medicine and infectious diseases

Study Record Dates

First Submitted

April 11, 2020

First Posted

April 14, 2020

Study Start

April 15, 2020

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

April 14, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations

EG(1)